Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma

Molecule-targeted therapy, such as sorafenib, is one of the effectively therapeutic options for advanced hepatocellular carcinoma (HCC). However, acquired resistance to sorafenib has been found in some HCC patients, resulting in poor prognosis. It is reported that PD-L1 and DNA methyltransferases (D...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jianhua, Liu, Yahui, Meng, Lingyu, Liu, Kai, Ji, Bai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561980/
https://www.ncbi.nlm.nih.gov/pubmed/28627705
http://dx.doi.org/10.3892/or.2017.5722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561980/
https://www.ncbi.nlm.nih.gov/pubmed/28627705
http://dx.doi.org/10.3892/or.2017.5722

Ejemplares similares